Clinical trials in crisis: Four simple methodologic fixes

Clinical Trials

Volumn 11, Issue 6, 2014, Pages 615-621

  Vickers, Andrew J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Randomized controlled trials; Research design

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COST; DISEASE COURSE; FOLLOW UP; HUMAN; INFORMED CONSENT; INTENTION TO TREAT ANALYSIS; METHODOLOGY; MORTALITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SELECTION; PHYSICIAN; QUALITY CONTROL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; ECONOMICS; PROCEDURES; STANDARDS; TOTAL QUALITY MANAGEMENT;

HUMANS; INFORMED CONSENT; QUALITY IMPROVEMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84911401492     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774514553681     Document Type: Article

References (41)

1. Dilts D. US cancer trials may go the way of the Oldsmobile. Nat Med 2010; 16: 632.
2. The New York Times. Faltering cancer trials. The New York Times, 2010, http://www.nytimes.com/2010/04/25/opinion/25sun1.html?-r=0
3. Cheng SK, Dietrich MS and Dilts DM. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin Cancer Res 2010; 16: 5557-5563.
4. Silverman E. Clinical trial costs are rising rapidly. Pharmalot, 26 July 2011.
5. Dilts DM, Sandler AB, Baker M, et al. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 4553-4557.
6. Yusuf S. Damage to important clinical trials by over-regulation. Clin Trials 2010; 7: 622-625.
7. Duley L, Antman K, Arena J, et al. Specific barriers to the conduct of randomized trials. Clin Trials 2008; 5: 40-48.
8. Eapen ZJ, Vavalle JP, Granger CB, et al. Rescuing clinical trials in the United States and beyond: a call for action. Am Heart J 2013; 165: 837-847.
9. Reith C, Landray M and Califf RM. Randomized clinical trials-removing obstacles. N Engl J Med 2013; 369: 2269.
10. Fuks A, Weijer C, Freedman B, et al. A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group. J Clin Epidemiol 1998; 51: 69-79.
11. Getz KA, Wenger J, Campo RA, et al. Assessing the impact of protocol design changes on clinical trial performance. Am J Ther 2008; 15: 450-457.
12. DeMets DL and Califf RM. A historical perspective on clinical trials innovation and leadership: where have the academics gone? JAMA 2011; 305: 713-714.
13. Yusuf S, Bosch J, Devereaux PJ, et al. Sensible guidelines for the conduct of large randomized trials. Clin Trials 2008; 5: 38-39.
14. Eisenstein EL, Collins R, Cracknell BS, et al. Sensible approaches for reducing clinical trial costs. Clin Trials 2008; 5: 75-84.
15. Armitage J, Souhami R, Friedman L, et al. The impact of privacy and confidentiality laws on the conduct of clinical trials. Clin Trials 2008; 5: 70-74.
16. Granger CB, Vogel V, Cummings SR, et al. Do we need to adjudicate major clinical events? Clin Trials 2008; 5: 56-60.
17. Baigent C, Harrell FE, Buyse M, et al. Ensuring trial validity by data quality assurance and diversification of monitoring methods. Clin Trials 2008; 5: 49-55.
18. Sackett DL. Why randomized controlled trials fail but needn't: 1. Failure to gain "coal-face" commitment and to use the uncertainty principle. CMAJ 2000; 162: 1311-1314.
19. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; 2: 57-66.
20. George SL. Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol 1996; 14: 1364-1370.
21. Saku K, Zhang B and Noda K. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J 2011; 75: 1493-1505.
22. Vickers AJ and Scardino PT. The clinically-integrated randomized trial: proposed novel method for conducting large trials at low cost. Trials 2009; 10: 14.
23. Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357: 1477-1486.
24. Pogue J, Walter SD and Yusuf S. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clin Trials 2009; 6: 239-251.
25. Vickers AJ, Bennette C, Touijer K, et al. Feasibility study of a clinically-integrated randomized trial of modifications to radical prostatectomy. Trials 2012; 13: 23.
26. Califf RM and Platt R. Embedding cardiovascular research into practice. JAMA 2013; 310: 2037-2038.
27. Hejblum G, Chalumeau-Lemoine L, Ioos V, et al. Comparison of routine and on-demand prescription of chest radiographs in mechanically ventilated adults: a multicentre, cluster-randomised, two-period crossover study. Lancet 2009; 374: 1687-1693.
28. Relton C, Torgerson D, O'Cathain A, et al. Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design. BMJ2010; 340: c1066.
29. Blajchman MA, Carson JL, Eikelboom JW, et al. The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. Transfusion 2012; 52: 1363-1378.
30. Heddle NM, Cook RJ, Arnold DM, et al. The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial. Transfusion 2012; 52: 1203-1212.
31. Fiore LD, Brophy M, Ferguson RE, et al. A point-of-care clinical trial comparing insulin administered using a sliding scale versus a weight-based regimen. Clin Trials 2011; 8: 183-195.
32. Vickers AJ, Savage CJ, Shouery M, et al. Validation study of a web-based assessment of functional recovery after radical prostatectomy. Health Qual Life Outcomes 2010; 8: 82.
33. Anastasiadis E, Ahmed HU, Relton, et al. A novel randomised controlled trial design in prostate cancer. BJU Int. Epub ahead of print 14 March 2014. DOI: 10.1111/bju.12735.
34. Truog RD, Robinson W, Randolph A, et al. Is informed consent always necessary for randomized, controlled trials? N Engl J Med 1999; 340: 804-807.
35. Kass NE, Faden RR, Goodman SN, et al. The research-treatment distinction: a problematic approach for determining which activities should have ethical oversight. Hastings Cent Rep 2013; 43: S4-S15.
36. Drazen JM, Solomon CG and Greene MF. Informed consent and SUPPORT. N Engl J Med 2013; 368: 1929-1931.
37. Pharoah PD. The US Office for Human Research Protections' judgment of the SUPPORT trial seems entirely reasonable. BMJ 2013; 347: f4637.
38. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ 2009; 180: E47-E57.
39. Yusuf S, Collins R and Peto R. Why do we need some large, simple randomized trials? Stat Med 1984; 3: 409-422.
40. Roehr B. The appeal of large simple trials. BMJ 2013; 346: f1317.
41. Zelen M. A new design for randomized clinical trials. N Engl J Med 1979; 300: 1242-1245.